NCT02455193 Neuronal Effects of Exercise in Schizophrenia
| NCT ID | NCT02455193 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2014-08 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2014-08 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to food images as well as asking questions about their food preferences and intake and clinical symptoms. The investigators may also ask participants to complete an exercise or diet intervention to see how this changes brain responses or food preferences.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of schizophrenia or schizoaffective disorder * Between 21 and 70 years of age * Currently prescribed either olanzapine, risperidone, clozapine, or haloperidol, OR not currently being treated with any neuroleptic medications * Weight stable within 5 percent for the last 6 months Exclusion Criteria: * Pregnancy * Substance abuse * Significant endocrine/metabolic disease (e.g., uncontrolled hypertension, severe hypertriglyceridemia) * MRI-specific exclusion criteria (e.g., claustrophobia, metal in the body)
Contact & Investigator
Jason Tregellas, Ph.D.
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT02455193 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02455193 currently recruiting?
Yes, NCT02455193 is actively recruiting participants. Contact the research team at kristina.legget@ucdenver.edu for enrollment information.
Where is the NCT02455193 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT02455193 clinical trial?
NCT02455193 is sponsored by University of Colorado, Denver. The principal investigator is Jason Tregellas, Ph.D. at University of Colorado, Denver. The trial plans to enroll 140 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.